Seegene Names John G. Hurrell as Senior Executive Vice

Seegene Names John G. Hurrell as Senior Executive Vice President 
GAITHERSBURG, MD and SEOUL, KOREA -- (Marketwire) -- 01/14/13 -- 
Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex
molecular technologies and multiplex molecular diagnostic tests,
today announced the appointment of Dr. John G. Hurrell as its new
Senior Executive Vice President. In this position, Dr. Hurrell will
run Seegene's B2B business unit responsible for global licensing,
OEM, and companion diagnostic deals with global top-tier healthcare
players, as well as widening customer base within the clinical
laboratory test market.  
"We are excited to have Dr. Hurrell join Seegene's leadership team,"
said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene. "John's
distinguished track record of growing companies in the healthcare
industry will be an asset as we continue to drive Seegene's growth
both organically and through strategic acquisitions." 
Most recently Dr. Hurrell was the President and General Manager of
Focus Diagnostics, a subsidiary of Quest Diagnostics. At Focus
Diagnostics Dr. Hurrell led the development and launch of more than
70 molecular tests and successfully gained 510(k) approvals for six
products.  
Prior to that Dr. Hurrell served as Vice President of Business
Development at Quest Diagnostics. He also held numerous management
positions at healthcare firms, including Senior Vice President and
General Manager of TriPath Oncology, a subsidiary of TriPath Imaging,
which was acquired by Becton, Dickinson and Company.  
About Seegene 
 Seegene is the world's leading developer of multiplex
molecular technologies and multiplex clinical molecular diagnostics
(M-MoDx). Seegene's core enabling technologies -- ACP(TM), DPO(TM),
READ, and qTOCE(TM) -- are the foundation for M-MoDx tests that can
simultaneously detect multiple targets with high sensitivity,
specificity and reproducibility. Seegene's products detect
multi-pathogens with great reliability and throughput, ultimately
providing the most economical basis for saving time, labor and cost.
Seegene aims to become one of the top five global molecular
diagnostics firms by 2015 and is actively pushing ahead with a series
of promising licensing deals with global top-tier healthcare players
to make its qTOCE(TM) technology become the new gold standard.  
For more information please visit www.seegene.com or call
+301-762-9066. 
Press Release
Contacts:
David L. Dolinger, Ph.D.
Seegene Inc. 
301-762-9066
dolinger@seegene.com
or
Constantine Theodoropulos
Base Pair Group
617-816-4637
constantine@basepairgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.